Table 4 The association between PPI or H2RA use and the risk of gastric cancer in the UK Biobank.

From: Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies

 

Users

Non-users

Unadjusted

HR (95% CI)

Adjusteda

HR (95% CI)

Gastric cancer, n

Person-years

Gastric cancer, n

Person-years

PPI user vs. non-user

  Main analysis (starting follow-up at 1 y)

44

208,807

206

1,949,341

1.53 (1.10, 2.12)

1.28 (0.86, 1.90)

  Male only

29

94,195

153

896,467

1.43 (0.96, 2.13)

1.14 (0.70, 1.87)

  Female only

15

114,611

53

1,052,874

1.94 (1.09, 3.47)

1.73 (0.86, 3.45)

  Adenocarcinoma

37

208,807

175

1,949,341

1.52 (1.07, 2.18)

1.18 (0.76, 1.83)

  Gastric cardia

15

208,807

86

1,949,341

1.26 (0.72, 2.18)

0.81 (0.40, 1.64)

  Gastric non-cardia

14

208,807

51

1,949,341

1.93 (1.06, 3.50)

1.44 (0.68, 3.06)

  Main additionally adjusting for H2RAb

44

208,807

206

1,949,341

1.53 (1.10, 2.12)

1.26 (0.84, 1.88)

  Main removing adjustment for GORD, oesophagitis and peptic ulcerc

44

208,807

206

1,949,341

1.53 (1.10, 2.12)

1.41 (1.00, 1.98)

  Main additionally adjusting for year of cohort entryd

44

208,807

206

1,949,341

1.53 (1.10, 2.12)

1.28 (0.86, 1.90)

  Starting follow-up at 2 y

30

162,955

170

1,525,464

1.28 (0.86, 1.89)

1.15 (0.73, 1.82)

  Starting follow-up at 3 y

22

117,731

122

1,105,366

1.28 (0.81, 2.02)

1.12 (0.65, 1.92)

Omeprazole user vs. non-user

  Main analysis (starting follow-up at 1 y)

25

122,860

225

2,035,288

1.43 (0.95, 2.17)

1.17 (0.74, 1.85)

Lansoprazole user vs. non-user

  Main analysis (starting follow-up at 1 y)

16

73,848

234

2,084,299

1.49 (0.90, 2.48)

1.21 (0.71, 2.08)

H2RA user vs. non-user

  Main analysis (starting follow-up at 1 y)

4

38,517

246

2,119,632

0.80 (0.30, 2.15)

0.49 (0.16, 1.56)

  1. aAdjusted for age at baseline, sex, socioeconomic status, alcohol, smoking, BMI, comorbidities at baseline (including diabetes, GORD, oesophagitis and peptic ulcer) and other medication uses at baseline (statins aand aspirin).
  2. bAdditionally adjusted for H2RA.
  3. cRemoving the GORD, oesophagitis and peptic ulcer adjustment from the main model.
  4. dAdditionally adjusted for year of cohort entry.
Back to article page